← Back to Screener
Tiziana Life Sciences Ltd. Common Shares (TLSA)
Price$1.24
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-39.04%
Price vs S&P 500 (4W)-21.51%
VGM Score34.06
Market Capitalization$147.38M
All Metrics
Book Value / Share (Quarterly)$0.08
P/TBV (Annual)10.35x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.07
Price vs S&P 500 (YTD)-24.94%
EPS (TTM)$-0.11
10-Day Avg Trading Volume0.27M
EPS Excl Extra (TTM)$-0.11
EPS (Annual)$-0.17
ROI (Annual)-305.91%
Cash / Share (Quarterly)$0.06
ROA (Last FY)-145.20%
EBITD / Share (TTM)$-0.16
ROE (5Y Avg)-404.34%
Cash Flow / Share (Annual)$-0.01
P/B Ratio16.02x
P/B Ratio (Quarterly)20.41x
Net Income / Employee (Annual)$-2,211,400
Net Interest Coverage (TTM)-1539.00x
ROA (TTM)-92.11%
EPS Incl Extra (Annual)$-0.17
Current Ratio (Annual)1.02x
Quick Ratio (Quarterly)1.65x
3-Month Avg Trading Volume0.18M
52-Week Price Return-12.06%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.05
52-Week High$2.60
EPS Excl Extra (Annual)$-0.17
26-Week Price Return-31.11%
Quick Ratio (Annual)1.01x
13-Week Price Return-13.89%
Total Debt / Equity (Annual)0.03x
Current Ratio (Quarterly)1.72x
Enterprise Value$140.23M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.03
3-Month Return Std Dev78.74%
Net Income / Employee (TTM)$-1,605,100
ROE (Last FY)-319.56%
Net Interest Coverage (Annual)-4.42x
EPS Basic Excl Extra (Annual)$-0.17
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$-0.11
ROI (TTM)-192.39%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.05
Price vs S&P 500 (52W)-36.42%
Year-to-Date Return-16.78%
5-Day Price Return-11.43%
EPS Normalized (Annual)$-0.17
ROA (5Y Avg)-135.30%
Month-to-Date Return-12.06%
Cash Flow / Share (TTM)$-0.15
EBITD / Share (Annual)$-0.17
LT Debt / Equity (Annual)1.24x
ROI (5Y Avg)-287.29%
LT Debt / Equity (Quarterly)1.24x
EPS Basic Excl Extra (TTM)$-0.11
P/TBV (Quarterly)10.35x
P/B Ratio (Annual)19.57x
Book Value / Share (Annual)$0.04
Price vs S&P 500 (13W)-22.14%
Beta0.24x
Revenue / Share (TTM)$0.00
ROE (TTM)-195.51%
52-Week Low$1.08
mGradeD
vgmGradeD
Show chart for
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TLSATiziana Life Sciences Ltd. Common Shares | — | — | D | $1.24 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Tiziana Life Sciences is a clinical-stage biotechnology company developing immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's lead candidate, Foralumab (a fully human anti-CD3 monoclonal antibody), is in development for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's disease, and other CNS indications. Its pipeline also includes programs for ALS.